XML 44 R28.htm IDEA: XBRL DOCUMENT v3.22.4

REVENUE (Tables)

3 Months Ended

Jan. 31, 2023

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:

			Three Months Ended January 31,
			2023																								2022
			Life Sciences and Applied Markets						Agilent CrossLab						Diagnostics and Genomics						Total						Life Sciences and Applied Markets						Agilent CrossLab						Diagnostics and Genomics						Total
			(in millions)
Revenue by Region
Americas			$	332					$	154					$	201					$	687					$	317					$	132					$	188					$	637
Europe			259						98						99						456						252						98						101						451
Asia Pacific			442						129						42						613						407						129						50						586
Total			$	1,033					$	381					$	342					$	1,756					$	976					$	359					$	339					$	1,674

The following table presents the company’s total revenue disaggregated by end markets and by revenue type:

									Three Months Ended
									January 31,
															2023						2022
												(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical															$	639					$	602
Chemicals and Advanced Materials															406						373
Diagnostics and Clinical															239						243
Food															160						158
Academia and Government															146						141
Environmental and Forensics															166						157
Total															$	1,756					$	1,674
Revenue by Type
Instrumentation															$	759					$	691
Non-instrumentation and other															997						983
Total															$	1,756					$	1,674

Contract Liabilities and Changes in Balances

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the three months ended January 31, 2023:

						Contract Liabilities
						(in millions)
Ending balance as of October 31, 2022						$	557
Net revenue deferred in the period						246
Revenue recognized that was included in the contract liability balance at the beginning of the period						(196)
Change in deferrals from customer cash advances, net of revenue recognized						(5)
Currency translation and other adjustments						21
Ending balance as of January 31, 2023						$	623

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration